Many pathogens synthesize inositolphosphorylceramide (IPC) as the major sphingolipid (SL), unlike the mammalian host where sphingomyelin or more complex SLs predominate. Thus, divergence between IPCS and mammalian sphingolipid synthases has prompted interest as a potential drug target. However, in the trypanosomatid protozoan Leishmania, promastigotes lacking de novo sphingolipid synthesis (∆spt2-) survive and remain virulent, as amastigotes salvage host sphingolipids and are still able to produce IPC. To further understand the role of IPC, we generated null IPCS mutants in L. major (Δipcs-). Unexpectedly and unlike fungi where IPCS is essential, Δipcs- was remarkably normal in culture and highly virulent in mouse infections. Both IPCS activity and IPC itself were absent in Δipcs- promastigotes and amastigotes, arguing against an alternative route of IPC synthesis. Notably, salvaged mammalian sphingomyelin was highly abundant in purified amastigotes from both WT and Δipcs-. Quantitative estimation showed SM to be about 5-fold more abundant than IPC in WT, suggesting that normally SM is the dominant amastigote SL. Analysis of the WT amastigote IPC ceramide anchor showed that it arose not from de novo synthesis by the parasite, but through catabolism of mammalian SLs, probably through the action of the parasite sphingomyelinase ISCL. These data suggest that SM salvage may account for the survival and virulence of Δipcs-, a finding which likely mitigates the suitability of IPCS as a chemotherapeutic target.